Novo Nordisk A (NVO) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Competitors, else..
 
Novo Nordisk A  (NYSE: NVO)
 

Novo Nordisk A Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NVO Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q1 MRQ) 37.57 % 11.97 % 3.9 % 5.68 %
Q / Q Revenue Growth (Q1 MRQ) -67.61 % 3.64 % 2.5 % 2.63 %
Y / Y Revenue Growth (for 12 months ending Q1 TTM) 16.24 % 40.43 % 22.92 % %
Sequential Revenue Growth (for 12 months ending Q1 TTM) 5.1 % 36.47 % 18.35 % 1.74 %
Revenue 5 Year Average Growth 73.9 % 14.14 % 10.99 % 7.73 %


NVO's Growth Comparisons in I. Quarter 2026




With 37.57% year on year Revenue increase in the first quarter 2026, Novo Nordisk A outperformed the 11.97% rise in the Major Pharmaceutical Preparations industry, and 3.9% growth in the Healthcare sector. Comparing the first quarter sales growth, both Major Pharmaceutical Preparations industry and Novo Nordisk A outperformed 5.68% overall market increase.

Top-line fell by -67.61% from the fourth quarter results. Comparing the annual growth, sales of 73.9% on average in last five years, to the S & P 500's, including only Businesses with the first quarter 2026 financial results, average yearly sales growth is 7.73%. Novo Nordisk A grew faster than the market.

NVO Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Obesity and Diabetes care
-
-
Obesity and Diabetes care segments
-
-
Rare disease
-
-
Rare disease segments
-
-
USA
-
-
Obesity and Diabetes care total
-
-
Rare disease total
-
-
Total GLP-1 Obesity and Diabetes care total
-
-
Ozempic Obesity and Diabetes care total
-
-
Rybelsus Obesity and Diabetes care total
-
-
Victoza Obesity and Diabetes care total
-
-
Total insulin Obesity and Diabetes care total
-
-
Long-acting insulin Obesity and Diabetes care total
-
-
Awigli Obesity and Diabetes care total
-
-
Tresiba Obesity and Diabetes care total
-
-
Xultophy Obesity and Diabetes care total
-
-
Levemir Obesity and Diabetes care total
-
-
Premix insulin Obesity and Diabetes care total
-
-
Ryzodeg Obesity and Diabetes care total
-
-
NovoMix Obesity and Diabetes care total
-
-
Fast-acting insulin Obesity and Diabetes care total
-
-
Fiasp Obesity and Diabetes care total
-
-
NovoRapid Obesity and Diabetes care total
-
-
Human insulin Obesity and Diabetes care total
-
-
Other Diabetes care Obesity and Diabetes care total
-
-
Total Diabetes care Obesity and Diabetes care total
-
-
Total Obesity care Obesity and Diabetes care total
-
-
Wegovy Obesity and Diabetes care total
-
-
Saxenda Obesity and Diabetes care total
-
-
Rare blood disorders Rare disease total
-
-
Haemophilia A Rare disease total
-
-
Haemophilia B Rare disease total
-
-
NovoSeven Rare disease total
-
-
Rare endocrine disorders Rare disease total
-
-
Other Rare disease Rare disease total
-
-
International Operations
-
-
International Operations Obesity and Diabetes care total
-
-
International Operations Rare disease total
-
-
International Operations Total GLP-1 Obesity and Diabetes care total
-
-
International Operations Ozempic Obesity and Diabetes care total
-
-
International Operations Rybelsus Obesity and Diabetes care total
-
-
International Operations Victoza Obesity and Diabetes care total
-
-
International Operations Total insulin Obesity and Diabetes care total
-
-
International Operations Long-acting insulin Obesity and Diabetes care total
-
-
International Operations Awigli Obesity and Diabetes care total
-
-
International Operations Tresiba Obesity and Diabetes care total
-
-
International Operations Xultophy Obesity and Diabetes care total
-
-
International Operations Levemir Obesity and Diabetes care total
-
-
International Operations Premix insulin Obesity and Diabetes care total
-
-
International Operations Ryzodeg Obesity and Diabetes care total
-
-
International Operations NovoMix Obesity and Diabetes care total
-
-
International Operations Fast-acting insulin Obesity and Diabetes care total
-
-
International Operations Fiasp Obesity and Diabetes care total
-
-
International Operations NovoRapid Obesity and Diabetes care total
-
-
International Operations Human insulin Obesity and Diabetes care total
-
-
International Operations Other Diabetes care Obesity and Diabetes care total
-
-
International Operations Total Diabetes care Obesity and Diabetes care total
-
-
International Operations Total Obesity care Obesity and Diabetes care total
-
-
International Operations Wegovy Obesity and Diabetes care total
-
-
International Operations Saxenda Obesity and Diabetes care total
-
-
International Operations Rare blood disorders Rare disease total
-
-
International Operations Haemophilia A Rare disease total
-
-
International Operations Haemophilia B Rare disease total
-
-
International Operations NovoSeven Rare disease total
-
-
International Operations Rare endocrine disorders Rare disease total
-
-
International Operations Other Rare disease Rare disease total
-
-
EUCAN
-
-
EUCAN Obesity and Diabetes care total
-
-
EUCAN Rare disease total
-
-
EUCAN Total GLP-1 Obesity and Diabetes care total
-
-
EUCAN Ozempic Obesity and Diabetes care total
-
-
EUCAN Rybelsus Obesity and Diabetes care total
-
-
EUCAN Victoza Obesity and Diabetes care total
-
-
EUCAN Total insulin Obesity and Diabetes care total
-
-
EUCAN Long-acting insulin Obesity and Diabetes care total
-
-
EUCAN Awigli Obesity and Diabetes care total
-
-
EUCAN Tresiba Obesity and Diabetes care total
-
-
EUCAN Xultophy Obesity and Diabetes care total
-
-
EUCAN Levemir Obesity and Diabetes care total
-
-
EUCAN Premix insulin Obesity and Diabetes care total
-
-
EUCAN Ryzodeg Obesity and Diabetes care total
-
-
EUCAN NovoMix Obesity and Diabetes care total
-
-
EUCAN Fast-acting insulin Obesity and Diabetes care total
-
-
EUCAN Fiasp Obesity and Diabetes care total
-
-
EUCAN NovoRapid Obesity and Diabetes care total
-
-
EUCAN Human insulin Obesity and Diabetes care total
-
-
EUCAN Other Diabetes care Obesity and Diabetes care total
-
-
EUCAN Total Diabetes care Obesity and Diabetes care total
-
-
EUCAN Total Obesity care Obesity and Diabetes care total
-
-
EUCAN Wegovy Obesity and Diabetes care total
-
-
EUCAN Saxenda Obesity and Diabetes care total
-
-
EUCAN Rare blood disorders Rare disease total
-
-
EUCAN Haemophilia A Rare disease total
-
-
EUCAN Haemophilia B Rare disease total
-
-
EUCAN NovoSeven Rare disease total
-
-
EUCAN Rare endocrine disorders Rare disease total
-
-
EUCAN Other Rare disease Rare disease total
-
-
Emerging Markets
-
-
Emerging Markets Obesity and Diabetes care total
-
-
Emerging Markets Rare disease total
-
-
Emerging Markets Total GLP-1 Obesity and Diabetes care total
-
-
Emerging Markets Ozempic Obesity and Diabetes care total
-
-
Emerging Markets Rybelsus Obesity and Diabetes care total
-
-
Emerging Markets Victoza Obesity and Diabetes care total
-
-
Emerging Markets Total insulin Obesity and Diabetes care total
-
-
Emerging Markets Long-acting insulin Obesity and Diabetes care total
-
-
Emerging Markets Tresiba Obesity and Diabetes care total
-
-
Emerging Markets Xultophy Obesity and Diabetes care total
-
-
Emerging Markets Levemir Obesity and Diabetes care total
-
-
Emerging Markets Premix insulin Obesity and Diabetes care total
-
-
Emerging Markets Ryzodeg Obesity and Diabetes care total
-
-
Emerging Markets NovoMix Obesity and Diabetes care total
-
-
Emerging Markets Fast-acting insulin Obesity and Diabetes care total
-
-
Emerging Markets Fiasp Obesity and Diabetes care total
-
-
Emerging Markets NovoRapid Obesity and Diabetes care total
-
-
Emerging Markets Human insulin Obesity and Diabetes care total
-
-
Emerging Markets Other Diabetes care Obesity and Diabetes care total
-
-
Emerging Markets Total Diabetes care Obesity and Diabetes care total
-
-
Emerging Markets Total Obesity care Obesity and Diabetes care total
-
-
Emerging Markets Wegovy Obesity and Diabetes care total
-
-
Emerging Markets Saxenda Obesity and Diabetes care total
-
-
Emerging Markets Rare blood disorders Rare disease total
-
-
Emerging Markets Haemophilia A Rare disease total
-
-
Emerging Markets Haemophilia B Rare disease total
-
-
Emerging Markets NovoSeven Rare disease total
-
-
Emerging Markets Rare endocrine disorders Rare disease total
-
-
Emerging Markets Other Rare disease Rare disease total
-
-
APAC
-
-
APAC Obesity and Diabetes care total
-
-
APAC Rare disease total
-
-
APAC Total GLP-1 Obesity and Diabetes care total
-
-
APAC Ozempic Obesity and Diabetes care total
-
-
APAC Rybelsus Obesity and Diabetes care total
-
-
APAC Victoza Obesity and Diabetes care total
-
-
APAC Total insulin Obesity and Diabetes care total
-
-
APAC Long-acting insulin Obesity and Diabetes care total
-
-
APAC Awigli Obesity and Diabetes care total
-
-
APAC Tresiba Obesity and Diabetes care total
-
-
APAC Xultophy Obesity and Diabetes care total
-
-
APAC Levemir Obesity and Diabetes care total
-
-
APAC Premix insulin Obesity and Diabetes care total
-
-
APAC Ryzodeg Obesity and Diabetes care total
-
-
APAC NovoMix Obesity and Diabetes care total
-
-
APAC Fast-acting insulin Obesity and Diabetes care total
-
-
APAC Fiasp Obesity and Diabetes care total
-
-
APAC NovoRapid Obesity and Diabetes care total
-
-
APAC Human insulin Obesity and Diabetes care total
-
-
APAC Other Diabetes care Obesity and Diabetes care total
-
-
APAC Total Diabetes care Obesity and Diabetes care total
-
-
APAC Total Obesity care Obesity and Diabetes care total
-
-
APAC Wegovy Obesity and Diabetes care total
-
-
APAC Saxenda Obesity and Diabetes care total
-
-
APAC Rare blood disorders Rare disease total
-
-
APAC Haemophilia A Rare disease total
-
-
APAC Haemophilia B Rare disease total
-
-
APAC NovoSeven Rare disease total
-
-
APAC Rare endocrine disorders Rare disease total
-
-
APAC Other Rare disease Rare disease total
-
-
Region China
-
-
Region China Obesity and Diabetes care total
-
-
Region China Rare disease total
-
-
Region China Total GLP-1 Obesity and Diabetes care total
-
-
Region China Ozempic Obesity and Diabetes care total
-
-
Region China Rybelsus Obesity and Diabetes care total
-
-
Region China Victoza Obesity and Diabetes care total
-
-
Region China Total insulin Obesity and Diabetes care total
-
-
Region China Long-acting insulin Obesity and Diabetes care total
-
-
Region China Awigli Obesity and Diabetes care total
-
-
Region China Tresiba Obesity and Diabetes care total
-
-
Region China Xultophy Obesity and Diabetes care total
-
-
Region China Levemir Obesity and Diabetes care total
-
-
Region China Premix insulin Obesity and Diabetes care total
-
-
Region China Ryzodeg Obesity and Diabetes care total
-
-
Region China NovoMix Obesity and Diabetes care total
-
-
Region China Fast-acting insulin Obesity and Diabetes care total
-
-
Region China NovoRapid Obesity and Diabetes care total
-
-
Region China Human insulin Obesity and Diabetes care total
-
-
Region China Other Diabetes care Obesity and Diabetes care total
-
-
Region China Total Diabetes care Obesity and Diabetes care total
-
-
Region China Total Obesity care Obesity and Diabetes care total
-
-
Region China Wegovy Obesity and Diabetes care total
-
-
Region China Saxenda Obesity and Diabetes care total
-
-
Region China Rare blood disorders Rare disease total
-
-
Region China Haemophilia A Rare disease total
-
-
Region China Haemophilia B Rare disease total
-
-
Region China NovoSeven Rare disease total
-
-
Region China Rare endocrine disorders Rare disease total
-
-
Region China Other Rare disease Rare disease total
-
-
USA Obesity and Diabetes care total
-
-
USA Rare disease total
-
-
USA Total GLP-1 Obesity and Diabetes care total
-
-
USA Ozempic Obesity and Diabetes care total
-
-
USA Rybelsus Obesity and Diabetes care total
-
-
USA Victoza Obesity and Diabetes care total
-
-
USA Total insulin Obesity and Diabetes care total
-
-
USA Long-acting insulin Obesity and Diabetes care total
-
-
USA Tresiba Obesity and Diabetes care total
-
-
USA Xultophy Obesity and Diabetes care total
-
-
USA Levemir Obesity and Diabetes care total
-
-
USA Premix insulin Obesity and Diabetes care total
-
-
USA NovoMix Obesity and Diabetes care total
-
-
USA Fast-acting insulin Obesity and Diabetes care total
-
-
USA Fiasp Obesity and Diabetes care total
-
-
USA NovoRapid Obesity and Diabetes care total
-
-
USA Human insulin Obesity and Diabetes care total
-
-
USA Other Diabetes care Obesity and Diabetes care total
-
-
USA Total Diabetes care Obesity and Diabetes care total
-
-
USA Total Obesity care Obesity and Diabetes care total
-
-
USA Wegovy Obesity and Diabetes care total
-
-
USA Saxenda Obesity and Diabetes care total
-
-
USA Rare blood disorders Rare disease total
-
-
USA Haemophilia A Rare disease total
-
-
USA Haemophilia B Rare disease total
-
-
USA NovoSeven Rare disease total
-
-
USA Rare endocrine disorders Rare disease total
-
-
USA Other Rare disease Rare disease total
-
-
Total
-
-


Growth Rates of NVO's Income in the first quarter 2026


NVO Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q1 MRQ) 70.52 % 163.92 % 43.13 % -0.27 %
Sequential Operating Income Change (Q1 MRQ) -51.71 % -36.21 % -18.21 % -8.98 %
Y / Y Operating Income Growth (Q1 TTM) 14.18 % 19.47 % 20.16 % 9.24 %
Sequential Operating Income Growth (Q1 TTM) 11.49 % 15.85 % 8.88 % -0.22 %
Operating Income 5 Year Avg. Change 18.47 % 0.11 % -0.96 % 9 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q1 MRQ) 85.68 % - -92.49 % 22.99 %
Sequential Income from Cont. Ops. Change (Q1 MRQ) -50.98 % - -92.34 % 8.13 %
Y / Y Income from Cont. Ops. Change (Q1 TTM) 18.02 % 19.86 % 64.46 % 11.58 %
Sequential Income from Cont. Ops. Change (Q1 TTM) 13.11 % 10.92 % 43.11 % 4.61 %
Income from Cont. Ops. 5 Year Avg. Change 19.19 % -18.69 % -17.93 % 8.34 %

NVO Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q1 MRQ) 85.56 % 124.96 % 34.43 % 25.85 %
Q / Q Net Income Growth (Q1 MRQ) -50.99 % 18.2 % -22.85 % 7.59 %
Y / Y Net Income Change (Q1 TTM) 18.01 % 79.49 % 65.39 % 9.66 %
Sequential Net Income Change (Q1 TTM) 13.1 % 111.37 % 70.85 % 5.18 %
Net Income 5 Year Avg. Growth 73.85 % 14.51 % 6.2 % 9.47 %

NVO's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q1 MRQ) 85.87 % - -92.49 % 22.99 %
Sequential EPS from Cont. Ops. Change (Q1 MRQ) - - -92.34 % 8.13 %
Y / Y EPS from Cont. Ops. Change (Q1 TTM) 34.41 % - - -
Sequential EPS from Cont. Ops. Change (Q1 TTM) 31.23 % - - 33 %
EPS from Cont. Ops. 5 Year Avg. Growth 75.63 % -29.42 % -17.93 % 8.34 %



NVO EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q1 MRQ) 85.87 % 113.67 % 34.43 % 8.34 %
Q / Q EPS Net Growth (Q1 MRQ) - 20.77 % -22.85 % 7.59 %
Y / Y EPS Net Change (for 12 months ending Q1 TTM) - - - 92.65 %
Sequential EPS Net Change (for 12 months ending Q1 TTM) 31.23 % - - 33 %
EPS Net 5 Year Avg. Change 75.58 % 14.51 % 6.2 % 9.47 %



Novo Nordisk A showed respectable 85.87% year on year rise of EPS in the first quarter, but comparing unfavorably to the 113.67% surge in the Major Pharmaceutical Preparations industry, but beating the 34.43% increase in the Healthcare sector. Above average income per share gains in Healthcare and Major Pharmaceutical Preparations industry, helped to elevate overall market growth to 25.85%.

Bottom-line fell by -67.61% from the fourth quarter results. Comparing the annual growth, income per share of 75.58% on average in last five years, to the S & P 500's, including only Businesses with the first quarter 2026 earnings, average yearly income per share growth is 9.47%. Novo Nordisk A grew faster than the market.

NVO Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q1 MRQ) 25.41 % 56.01 % 46.59 % 32.85 %
Sequential Free Cash Flow Change (Q1 MRQ) - -26.02 % -0.82 % 113.08 %
Y / Y Free Cash Flow Change (Q1 TTM) -21.17 % 13.97 % 16.86 % 10.44 %
Sequential Free Cash Flow Change (Q1 TTM) 4.69 % 8.12 % 8.13 % 9.43 %
Free Cash Flow 5 Year Avg. Change 25.15 % 9.45 % 6.34 % 10.76 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q1 MRQ) - -83.27 % - -81.15 %
Sequential Net Cash Flow Change (Q1 MRQ) - - - -
Y / Y Net Cash Flow Change (Q1 TTM) - -1 % 0.04 % -
Sequential Net Cash Flow Change (Q1 TTM) - 25.87 % 111.57 % -
Net Cash Flow 5 Year Avg. Change - -8.21 % -1.7 % -32.35 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q1 MRQ) - 2.15 % 7.41 % 22.34 %
Sequential Capital Expenditures Change (Q1 MRQ) - 25.33 % 22.68 % 17.09 %
Y / Y Capital Expenditures Change (Q1 TTM) - 13.78 % 7.84 % 41.57 %
Sequential Capital Expenditures Change (Q1 TTM) - 12.29 % 6.37 % 6.83 %
Capital Expenditures 5 Year Avg. Change - 10.12 % 8.7 % 10.66 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.